SNIPR001 is an orally administered, CRISPR-armed bacteriophage therapeutic developed by SNIPR Biome for the prevention of bloodstream infections caused by Escherichia coli in patients with haematological malignancies undergoing haematopoietic stem-cell transplantation. SNIPR001 is designed to selectively target and eliminate fluoroquinolone-resistant E. coli colonising the gut, thereby reducing the risk of bacterial translocation into the bloodstream in immunocompromised patients. The therapy employs CRISPR-Cas technology delivered via engineered bacteriophages to achieve species-specific bacterial targeting while sparing the broader gut microbiome. SNIPR001 has received FDA Fast Track designation for prophylaxis of bloodstream E. coli infections.
Disease: E. coli infections, (NCT06938867)
To see all details you need to have a subscription token. Click here for more details
Candidate summary:
Disease/Disease category:
- Bacterial infectious diseases
Official title:
A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia Coli Pre-Transplant
Phases:
- Phase 1
- Phase 2
Status:
Active recruiting
Country:
- United States
